Table 1.
Baseline characteristics of the study population
| All subjects n = 1713 | Deceased n = 590 | Incident HF n = 130 | Incident CE n = 189 | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 67.4 (±6.0) | 70.9 (±4.9) | 70.4 (±4.8) | 69.0 (±5.6) |
| Women, n (%) | 498 (29.1) | 179 (30.3) | 28 (21.5) | 28 (14.8) |
| Smoking, n (%) | 303 (17.7) | 125 (21.2) | 23 (17.7) | 32 (16.9) |
| Clinical profile | ||||
| BMI (kg/m2) | 28.3 (±4.3) | 28.5 (±4.6) | 29.5 (±5.0) | 28.0 (±3.9) |
| Systolic BP (mmHg) | 146.6 (±20.2) | 146.5 (±21.1) | 148.2 (±21.5) | 151.6 (±20.8) |
| Heart rate (BPM) | 71.8 (±12.5) | 72.0 (12.5) | 70.5 (±14.4) | 71.1 (±12.5) |
| Medical history | ||||
| Diabetes, n (%) | 604 (35.3) | 298 (50.5) | 72 (55.4) | 88 (46.6) |
| Prevalent HF, n (%) | 30 (1.8) | 25 (4.3) | N/A | N/A |
| Prevalent AF, n (%) | 97 (5.7) | 65 (11.0) | 16 (12.3) | 13 (6.9) |
| Prevalent CVD, n (%) | 185 (10.8) | 100 (16.9) | 41 (31.5) | N/A |
| AHT, n (%) | 802 (46.8) | 348 (59.0) | 86 (66.2) | 104 (55.0) |
| Laboratory | ||||
| Cystatin C (mg/L) | 1.06 (0.95–1.20) | 1.14 (0.99–1.33) | 1.16 (1.0–1.3) | 1.12 (0.99.1.29) |
| NT‐proBNP (pg/mL) | 12 (6–25) | 21 (10–45) | 32 (15–69) | 14 (7–33) |
| Cholesterol (mmol/L) | 5.40 (4.6–6.2) | 5.2 (4.4–6.0) | 5.0 (4.1–5.7) | 5.5 (4.7–6.2) |
| HDL‐C (mmol/L) | 1.25 (1.03–1.52) | 1.24 (1.03–1.50) | 1.20 (1.0–1.4) | 1.22 (0.97–1.43) |
AF, atrial fibrillation; AHT, anti‐hypertensive treatment; BMI, body mass index; BP, blood pressure; BPM, beats per minute; CE, coronary event; CVD, cardiovascular disease; HDL, high‐density lipoprotein; HF, heart failure; N/A not applicable, excluded prior to analysis; NT‐proBNP; N‐terminal pro‐B‐type natriuretic peptide.
Values are displayed as means (±standard deviation) or, for skewed variables, medians and interquartile (25–75) range.